| Name | Title | Contact Details |
|---|
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
MicroSurgical Technology is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cherry Health is an independent, non-profit Federally Qualified Health Center (FQHC) with a primary focus of providing high quality health services to those who have little or no access to health care, regardless of income or insurance status. Services provided by Cherry Health include primary care, women`s health, pediatrics, dental, vision, behavioral health, mental health, correctional health, five school based health centers and employee assistance for employers. Cherry Health provides services to all individuals, regardless of their ability to pay. A sliding fee payment scale based on income and family size is available to those without insurance. Medicaid and Healthy Michigan are accepted, as are many other insurances. Established in 1988, Cherry Health is the largest FQHC in the state of Michigan serving Barry, Eaton, Kent, Montcalm and Wayne counties at more than 20 locations, 14 of which are primary care Federally Qualified Health Center sites, Cherry Health employs over 800 employees and a network of over 60 physicians and mid-level providers specializing in primary care/family medicine, pediatrics, internal medicine, obstetrics/gynecology, optometry and psychiatry. Additionally, Cherry Health runs a school linked program active in 70 public schools offering both vision and dental care.
Innovative Health Applications is a Cape Canaveral, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Bernard Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Chicago, IL. To find more information about St. Bernard Hospital, please visit www.stbh.org